Gyre Therapeutics, Inc. GYRE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Gyre Pharmaceuticals | $117.05M+0.4% | $116.59M+8.7% | $107.27M+5.0% | $102.19M+1.5% | $100.64M-4.8% | |
| Other Nonoperating Income Expense by Business | ||||||
| Gyre | $113K+442% | -$33K-121% | $154K+215% | -$134K+61.8% | -$351K-4.5% | |
| Gyre Pharmaceuticals | -$1.7M-15.2% | -$1.47M-33.2% | -$1.11M+31.7% | -$1.62M-21.8% | -$1.33M0.0% | |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest by Business | ||||||
| All Other Segments | -$22K-15.8% | -$19K— | —— | —— | —— | |
| Gyre | -$12.03M-132% | -$5.19M— | —— | —— | —— | |
| Gyre Pharmaceuticals | $8.34M-44.7% | $15.09M-4.7% | $15.83M+20.7% | $13.12M+3.4% | $12.69M-24.0% | |
| Operating Income by Business | ||||||
| All Other Segments | -$22K-15.8% | -$19K— | —— | —— | —— | |
| Gyre | -$13.31M-56.8% | -$8.49M-20.8% | -$7.03M-1.7% | -$6.91M-15.1% | -$6M-2.5% | |
| Gyre Pharmaceuticals | $13.19M-34.0% | $19.99M+4.8% | $19.07M+17.3% | $16.26M-0.7% | $16.37M-25.6% | |
| Operating Expenses by Business | ||||||
| All Other Segments | $22K+15.8% | $19K— | —— | —— | —— | |
| Gyre | $13.31M+56.8% | $8.49M+20.8% | $7.03M+1.7% | $6.91M+15.1% | $6M+2.5% | |
| Gyre Pharmaceuticals | $104.76M+7.5% | $97.49M+10.6% | $88.12M+1.8% | $86.53M+1.5% | $85.25M+1.8% | |
| Income Tax Expense Benefit by Business | ||||||
| Gyre Pharmaceuticals | $4.27M-6.1% | $4.55M+31.8% | $3.46M+21.7% | $2.84M-22.7% | $3.67M-30.9% | |
| Cost of Goods Sold by Business | ||||||
| Gyre Pharmaceuticals | $5.75M+6.1% | $5.42M+11.7% | $4.85M+16.0% | $4.18M+10.0% | $3.8M-2.2% | |
| Total Assets by Business | ||||||
| All Other Segments | $1.44M-0.6% | $1.44M-0.8% | $1.46M-27.6% | $2.01M-21.4% | $2.56M-17.6% | |
| Gyre | $111.81M+18.2% | $94.58M+21.3% | $78M+30.8% | $59.65M+52.8% | $39.04M-10.7% | |
| Gyre Pharmaceuticals | $526.93M+2.9% | $511.93M+5.0% | $487.77M+3.5% | $471.42M+2.5% | $459.77M+2.9% | |
| Selling And Marketing Expense by Business | ||||||
| Gyre Pharmaceuticals | $68.47M+5.1% | $65.18M+12.0% | $58.22M+2.9% | $56.59M+1.4% | $55.81M-3.0% | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||||
| Gyre Pharmaceuticals | $14.94M+19.5% | $12.5M+3.4% | $12.1M-3.3% | $12.5M+2.1% | $12.24M+9.1% | |
| Gyre | $2.4M+101% | $1.2M+140% | $498K-1.0% | $503K-27.4% | $693K-13.4% | |
| General And Administrative Expense by Business | ||||||
| All Other Segments | $22K+15.8% | $19K— | —— | —— | —— | |
| Gyre | $8.35M+14.6% | $7.29M+11.7% | $6.53M+1.9% | $6.41M+20.6% | $5.31M+5.0% | |
| Gyre Pharmaceuticals | $14.7M+8.9% | $13.49M+3.6% | $13.03M+2.9% | $12.66M+2.5% | $12.35M+11.8% | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| Gyre Pharmaceuticals | $1.25M+4.7% | $1.19M+13.8% | $1.05M-2.3% | $1.07M-52.8% | $2.27M-4.0% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Gyre | $3.05M+16.9% | $2.61M+10.5% | $2.36M+31.9% | $1.79M+43.3% | $1.25M+50.3% | |
| Gyre Pharmaceuticals | $6.18M+35.9% | $4.55M— | —— | —— | —— | |
| Fair Value Adjustment Of Warrants by Business | ||||||
| Gyre | -$541K+80.0% | -$2.71M-2.6% | -$2.64M-8.4% | -$2.43M+52.6% | -$5.13M+28.4% | |
| Revenue (Gross) by Product | ||||||
| Contiva | $5.52M0.0% | $5.52M— | —— | —— | —— | |
| Concentration Risk % by Product | ||||||
| Contiva | 14.4%+2.5pp | 11.9%— | —— | —— | —— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 2800.0% | 280— | —— | —— | —— | |
| Shanghai | 8960.0% | 896— | —— | —— | —— | |
| Zhengzhou | 7200.0% | 720— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
